Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
ALAB notice of proposed sale of 33,000 shares of Common Stock through broker Morgan Stanley Smith Barney LLC. The shares were acquired 11/30/2018 in a Private Acquisition from Issuer or an Affiliate and are listed with a value of $15,939,660.00. The form references NASDAQ and a date of 07/01/2026.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice to sell 150,000 shares of Common Stock of ALAB listed on NASDAQ. The shares were acquired privately on 03/21/2018 and the proposed sale method is listed as cash. The excerpt shows an associated aggregate figure of $72,453,000 and 171,407,939 shares outstanding as of 07/01/2026.
ALAB reported proposed and recent sales of Common stock in a Form 144 notice, listing securities to be sold and multiple transactions by a named holder. The filing lists selling-party transactions and earlier private placement distributions from Sutter Hill Ventures A CA LP.
Examples in the filing show recent sales by Stefan Dyckerhoff: 11,599 shares on 04/17/2026 for $2,029,828.00, 13,399 shares on 04/20/2026 for $2,346,435.00, 12,499 shares on 05/07/2026 for $2,500,174.00, and 12,499 shares on 06/03/2026 for $4,553,995.00. The filing also records prior private placement receipts and pro‑rata distributions dated 02/07/2020 through 05/17/2022 from Sutter Hill Ventures A CA LP.
Astera Labs, Inc. director Bethany Mayer reported open-market sales of 686 shares of Common Stock on June 24, 2026. The transactions were executed in multiple tranches at weighted average prices reported between $391.2689 and $399.9600, with underlying trade ranges from $391.1300 to $398.6100 as described in the footnotes.
The sales occurred automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2024. Following these transactions, Mayer holds 5,550 shares directly and 839 shares indirectly through The Jantzen/Mayer Family 2002 Trust, for which she disclaims beneficial ownership beyond any pecuniary interest.
Astera Labs director Jack R. Lazar reported net share sales and an equity grant. On June 4, 2026 he sold 10,000 shares of Common Stock in open-market transactions under a Rule 10b5-1 trading plan at prices between $339.5600 and $362.8405 per share, and now directly holds 75,688 shares. He also received a grant of 837 restricted stock units that vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service.
Astera Labs, Inc. director Michael E. Hurlston received an equity award of 837 shares of common stock in the form of restricted stock units (RSUs) on June 4, 2026. After this grant, he holds 92,482 shares directly, including deferred stock units and dividend equivalent units. The RSU award will vest in full on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues his service. Each RSU converts into one share of Astera Labs common stock when it vests.
BARRATT CRAIG H reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs, Inc. director Craig H. Barratt received an award of 837 restricted stock units on June 4, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continuous service with the company through the vesting date. Following this grant, Barratt directly holds 6,825 shares of common stock.
Mayer Bethany reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs director Bethany Mayer received an equity award and reported trust holdings. She was granted 837 restricted stock units (RSUs) of Astera Labs, Inc. common stock on June 4, 2026 under the company’s 2024 Stock Option and Incentive Plan.
The RSU award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continuous service. After this grant, she holds 6,236 shares directly. A separate 839 Astera Labs shares are held indirectly by The Jantzen/Mayer Family 2002 Trust, where she is a trustee and disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. reported the results of its 2026 Annual Stockholders Meeting held on June 4, 2026. There were 171,281,952 common shares entitled to vote, and 141,439,565 were represented in person or by proxy.
Stockholders elected all three Class II directors to serve until the 2029 annual meeting. They also ratified PricewaterhouseCoopers LLP as the independent auditor, approved on an advisory basis the compensation of named executive officers, and supported holding future advisory votes on executive pay every one year.